866 related articles for article (PubMed ID: 19593085)
1. Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review.
Pollack SM; O'Connor TP; Hashash J; Tabbara IA
Am J Clin Oncol; 2009 Dec; 32(6):618-28. PubMed ID: 19593085
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
4. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges.
Satwani P; Harrison L; Morris E; Del Toro G; Cairo MS
Biol Blood Marrow Transplant; 2005 Jun; 11(6):403-22. PubMed ID: 15931629
[TBL] [Abstract][Full Text] [Related]
7. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience.
Shimoni A; Nagler A
Curr Hematol Rep; 2004 Jul; 3(4):242-8. PubMed ID: 15217553
[TBL] [Abstract][Full Text] [Related]
8. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches.
Friedman TM; Varadi G; Hopely DD; Filicko J; Wagner J; Ferber A; Martinez J; Brunner J; Grosso D; McGuire L; Korngold R; Flomenberg N
Biol Blood Marrow Transplant; 2001; 7(12):656-64. PubMed ID: 11787528
[TBL] [Abstract][Full Text] [Related]
9. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
Giralt S
Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
[TBL] [Abstract][Full Text] [Related]
10. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
[TBL] [Abstract][Full Text] [Related]
11. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
12. Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases.
Satwani P; Morris E; Bradley MB; Bhatia M; van de Ven C; Cairo MS
Pediatr Blood Cancer; 2008 Jan; 50(1):1-8. PubMed ID: 17668859
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Barosi G; Bacigalupo A
Curr Opin Hematol; 2006 Mar; 13(2):74-8. PubMed ID: 16456372
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell therapy for malignant diseases.
Shapira MY; Hai AA; Tsirigotis P; Resnick IB; Or R; Slavin S
Ann Med; 2007; 39(6):465-73. PubMed ID: 17852026
[TBL] [Abstract][Full Text] [Related]
15. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse.
Yakoub-Agha I; Saule P; Magro L; Cracco P; Duhamel A; Coiteux V; Bruno B; Dufossé F; Jouet JP; Dessaint JP; Labalette M
Biol Blood Marrow Transplant; 2009 Apr; 15(4):496-504. PubMed ID: 19285638
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning in primary refractory prolymphocytic leukemia: graft-versus-leukemia effect without graft-versus-host disease.
Castagna L; Nozza A; Bertuzzi A; Siracusano L; Timofeeva I; Santoro A
Bone Marrow Transplant; 2001 Dec; 28(12):1155-6. PubMed ID: 11803359
[TBL] [Abstract][Full Text] [Related]
17. [Ten years of changes in conditioning regimen for allogenic hematopoietic stem cell transplantation in adults].
Peffault de Latour R; Cabrespine-Faugeras A; Bay JO
Bull Cancer; 2008 Jan; 95(1):87-97. PubMed ID: 18230574
[TBL] [Abstract][Full Text] [Related]
18. Differences between the different conditioning regimens for allogeneic stem cell transplantation.
Schattenberg AV; Levenga TH
Curr Opin Oncol; 2006 Nov; 18(6):667-70. PubMed ID: 16988592
[TBL] [Abstract][Full Text] [Related]
19. Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies.
Kim I; Yoon SS; Lee KH; Keam B; Kim TM; Kim JS; Kim HG; Oh MD; Han KS; Park MH; Park S; Kim BK
Clin Transplant; 2006; 20(4):496-503. PubMed ID: 16842528
[TBL] [Abstract][Full Text] [Related]
20. [Outcome of allogeneic stem cell transplantation for hematological disorders in patients older than 50].
Fujimaki K; Takasaki H; Takabayashi M; Yamaji S; Koharazawa H; Kanamori H; Ishigatsubo Y
Gan To Kagaku Ryoho; 2005 Jan; 32(1):47-51. PubMed ID: 15675581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
